Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Development of Warfarin-Related Pharmacogenomics and Its Prospect of Clinical Application

Advances in Research and Clinical Application of Warfarin Pharmacogenomics

Pharmacogenetics of Target Genes Across the Warfarin Pharmacological Pathway

Role of Warfarin Pharmacogenetic Testing in Clinical Practice

A1640 Effect of CYP2C9 and VKORC1 gene polymorphism on warfarin steady-state therapeutic dose and individual anticoagulation efficacy

Development of Warfarin Daily Dose Adjustment Formula Based on Geno-type and INR

Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation

Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients

Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients

Estimation of the Warfarin Dose with A Pharmacogenetic Refinement Algorithm in Chinese Patients Mainly under Low-Intensity Warfarin Anticoagulation

Effect of VKORC1 and CYP2C9 gene polymorphism and linkage disequilibrium on the clinical application of warfarin

Individualized treatment of warfarin in atrial fibrillation patients

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients

Construction and Validation of A Pharmacogenetic Refinement Algorithm for the Estimation of the Warfarin Dose in Chinese Patients

Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.

Genetic factors contribute to patient-specific warfarin dose for Han Chinese.

To Establish a Method for Detecting Genetic Polymorphism of CYP2C9 1075A>C and VKORC1-1639 G>A and Evaluate the Correlation of SNP with Warfarin Dose

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Impact of VKORC1 Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement--a Systematic Review and Meta Analysis.

Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients.

Comparative Performance of Gene-Based Warfarin Dosing Algorithms in Chinese Patients